{
    "clinical_study": {
        "@rank": "149827", 
        "acronym": "AAPI", 
        "arm_group": [
            {
                "arm_group_label": "auricular acupuncture(AA) & placebo", 
                "arm_group_type": "Experimental", 
                "description": "vaccaria seed will be chosen as auricular acupuncture material to attach every 3 days for 28 days, meanwhile, oral placebo will be applied 15 mins before going to sleep everyday for 28 days."
            }, 
            {
                "arm_group_label": "sham AA &  Eszopiclone", 
                "arm_group_type": "Sham Comparator", 
                "description": "Acupoints without certain effect for primary insomnia will be chosen to attach every 3 days for 28 days, meanwhile, Eszopiclone will be applied 15 mins before going to sleep everyday for 28 days."
            }
        ], 
        "brief_summary": {
            "textblock": "This double-blind and double-dummy RCT will evaluate the therapeutic effectiveness and\n      safety of auricular acupuncture(AA) for primary insomnia(PI) ."
        }, 
        "brief_title": "Auricular Acupuncture for Primary Insomnia", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Insomnia", 
        "condition_browse": {
            "mesh_term": "Sleep Initiation and Maintenance Disorders"
        }, 
        "detailed_description": {
            "textblock": "Investigators will conduct a 2-year clinical trial on  auricular acupuncture (AA) for\n      primary insomnia (PI), which is a double-blind ( patient-blind and assessor-blind) and\n      double-dummy RCT. 288 patients will be randomly assigned into 2 groups: the treatment group\n      (Group A) and the control group (Group B). Group A will be treated with AA pressure plus\n      oral placebo, while Group B will be treated with sham AA pressure plus oral Eszopiclone. All\n      patients will receive a continuous 4-week treatment and 28-week follow-up. The data will be\n      analyzed by the third party who is not clear about allocation and treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meet the diagnosis of PI according to DSM-5;\n\n          -  Aged 18-64 (including 18 and 64);\n\n          -  Provided a signed written consent form.\n\n        Exclusion Criteria:\n\n          -  The patient has somatic disease like severe respiratory, circulatory, endocrine\n             system disease and hepatic/renal insufficiency;\n\n          -  The patient suffers from moderate / major depression (BDI score \u2267 8 points), moderate\n             / severe anxiety disorder (SAS score \u2267 61 points) or any other serious mental\n             disease;\n\n          -  The patient who abuse drug alcohol or substance;\n\n          -  The patient suffers from dementia or any other severe cognitive impairment;\n\n          -  The patient is in pregnancy or lactation period;\n\n          -  Patient who is a night worker or stick to irregular sleep pattern, and can't or don't\n             want to terminate this kind of work mode;\n\n          -  The patient has history of suicide or suicidal tendency;\n\n          -  The patient is allergic to Eszopiclone or any other sedative-hypnotic drugs;\n\n          -  The patient who has taken psychiatric, hypnotic or antihistamine drugs during the\n             last 4 weeks before baseline, however, the patient who use the prescription or\n             nonprescription hypnotic drugs no more than twice a week can be recruited as soon as\n             drug withdrawal;\n\n          -  The patient who is receiving ongoing psychological treatment;\n\n          -  The patient who has obstructive sleep apnea, restless leg syndrome, sleep rhythm\n             disorders, parasomnias, etc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "288", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087488", 
            "org_study_id": "2011SZ0302-3"
        }, 
        "intervention": [
            {
                "arm_group_label": "auricular acupuncture(AA) & placebo", 
                "description": "Auricular acupoints: Shenmen (TF4),  Heart (CO15), Subcortex (AT4), modifying points according to different patterns.\nAuricular attachment material: vaccaria seed.\nVaccaria seed manufacturer: Taicheng science and technology development limited company, Shanghai.\nProduction license: Shanghai  Food and Drug Administration production permit NO.20041117.\nTreatment frequency: every 3 days.\nDuration: 28 days.", 
                "intervention_name": "auricular acupuncture(AA)", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "sham AA &  Eszopiclone", 
                "description": "Auricular acupoints: Wrist (SF1), Clavicle (SF6), Shoulder (SF4\u30015), Tooth (LO1), Tonsil (LO7, 8, 9), modifying points according to different patterns.\nAuricular attachment material: vaccaria seed.\nVaccaria seed manufacturer: Taicheng science and technology development limited company, Shanghai.\nProduction license: Shanghai  Food and Drug Administration production permit NO.20041117.\nTreatment frequency: every 3 days.\nDuration: 28 days", 
                "intervention_name": "sham AA", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "sham AA &  Eszopiclone", 
                "description": "Dosage form: tablet.\nDosage: 1 piece (3mg).\nDrug manufacturer: Kanghong pharmaceutical  limited liability company, Chengdu.\nProduction license: NO. H20100074 approved by the state.\nTreatment frequency: 15 mins before going to bed everyday.\nDuration: 28days", 
                "intervention_name": "Eszopiclone", 
                "intervention_type": "Drug", 
                "other_name": "Lunesta or Estorra"
            }, 
            {
                "arm_group_label": "auricular acupuncture(AA) & placebo", 
                "description": "The dosage form (shape, color, size) and dosage of placebo is similar to Eszopiclone.\nPlacebo manufacturer: Kanghong pharmaceutical  limited liability company, Chengdu.\nTreatment frequency: 15 mins before going to bed everyday.\nDuration: 28days.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "placebo for Eszopiclone"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Eszopiclone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Primary insomnia", 
            "Auricular acupuncture"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "contact": {
                "email": "acu973@126.com", 
                "last_name": "Fanrong Liang, Professor", 
                "phone": "86-13608058216"
            }, 
            "facility": {
                "address": {
                    "city": "Chengdu", 
                    "country": "China", 
                    "state": "Sichuan", 
                    "zip": "610075"
                }, 
                "name": "Chengdu university of Traditonal Chinese Medcine"
            }, 
            "investigator": [
                {
                    "last_name": "Xi Wu, A.P.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Xiangdong Tang, Professor", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Caiqin Ming, Postgraduate", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lin Yuan, Postgraduate", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Huijuan Tan, Postgraduate", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Handan Zhang, Postgraduate", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Li Wu, Postgraduate", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Auricular Acupuncture for Primary Insomnia", 
        "overall_contact": {
            "email": "acu973@126.com", 
            "last_name": "Fanrong Liang, Professor", 
            "phone": "86-13608058216"
        }, 
        "overall_official": [
            {
                "affiliation": "Faculty of Acupuncture & Tuina\uff0cChengdu University of Traditional Chinese Medicine", 
                "last_name": "Fanrong Liang, Professor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Faculty of Acupuncture & Tuina\uff0cChengdu University of Traditional Chinese Medicine", 
                "last_name": "Xi Wu, A.P.", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Science and Technology", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "SOL is one of the sleep parameters mainly measured by actigraphy and sleep diaries, referring to the time it takes to fall asleep, starting from the moment of having intention to fall asleep, stopping at the moment of getting a 5-minute continuous sleep.", 
            "measure": "Sleep Onset Latency(SOL)", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline in SOL at 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087488"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chengdu University of Traditional Chinese Medicine", 
            "investigator_full_name": "Wu Xi", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pittsburgh Sleep Quality Index(PSQI)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in PSQI at 4 weeks"
            }, 
            {
                "measure": "Insomnia Severity Index (ISI)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in ISI at 4 weeks"
            }, 
            {
                "measure": "Beck Depression Inventory (BDI)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in BDI at 4 weeks"
            }, 
            {
                "measure": "State-Trait Anxiety Inventory (STAI)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in STAI at 4 weeks"
            }, 
            {
                "measure": "Self-rating Anxiety Scale (SAS)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in SAS at 4 weeks"
            }, 
            {
                "measure": "The Epworth Sleeping Scale (ESS)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in ESS at 4 weeks"
            }, 
            {
                "measure": "Flinders Fatigue Scale (FFS)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in FFS at 4 weeks"
            }, 
            {
                "measure": "The MOS 36-Item Short-Form Health Survey questionnaire (SF-36)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in SF-36 at 4 weeks"
            }, 
            {
                "description": "TST is one of the sleep parameters mainly measured by actigraphy and sleep diaries, referring to actually time slept, it's the amount of time from the initial sleep to final awakening, excluding the awake time.", 
                "measure": "Total Sleep Time (TST)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in TST at 4 weeks"
            }, 
            {
                "description": "SE is one of the sleep parameters mainly measured by actigraphy and sleep diaries, sleep efficiency percentage = [total sleep time/total time in bed] \u00d7100%.", 
                "measure": "Sleep Efficiency (SE)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in SE at 4 weeks"
            }, 
            {
                "description": "WASO is one of the sleep parameters mainly measured by actigraphy and sleep diaries, referring to the total time of awakening which from the initial sleep onset to the last awakening.", 
                "measure": "Wake After Sleep Onset (WASO)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline in WASO at 4 weeks"
            }
        ], 
        "source": "Chengdu University of Traditional Chinese Medicine", 
        "sponsors": {
            "collaborator": {
                "agency": "West China Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Chengdu University of Traditional Chinese Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}